

COBRA BIOMANUFACTURING EBT LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2018

Company Registration Number 05802963

WEDNESDAY



A88F04QQ

A07

26/06/2019

#217

COMPANIES HOUSE

COBRA BIOMANUFACTURING EBT LIMITED

CONTENTS

CONTENTS	PAGE
Company Information	1
Report of the Directors	2
Balance Sheet	3
Notes to the Financial Statements	4

COBRA BIOMANUFACTURING EBT LIMITED

COMPANY INFORMATION

Board of directors	Peter Coleman Lee Warren
Company secretary	Lee Warren
Registered office	Stephenson Building The Science Park Keele Staffordshire ST5 5SP

COBRA BIOMANUFACTURING EBT LIMITED
Registered Number 05802963

REPORT OF THE DIRECTORS
31 DECEMBER 2017


The directors present their annual report together with the unaudited financial statements of the company for the year ended 31 December 2018. The company is dormant and has not traded during the year.

Directors

The directors who served the Company throughout the year were as follows:

Peter Coleman
Lee Warren

Signed by order of the Board on its behalf by



Lee Warren
Company Secretary

Approved by the directors on **17 JUNE** 2019.

COBRA BIOMANUFACTURING EBT LIMITED

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 DECEMBER 2017


	Note	2018 £	2017 £
Current liabilities			
Creditors: amounts falling due within one year	3	<u>(438)</u>	<u>(438)</u>
Net liabilities		<u>(438)</u>	<u>(438)</u>
 Capital and reserves			
Called up share capital		1	1
Profit and loss account – (Deficit)		<u>(439)</u>	<u>(439)</u>
Total deficit on shareholders' funds		<u>(438)</u>	<u>(438)</u>


For the financial year ended 31 December 2018 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 and the members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 3 to 4 were approved by the directors and authorised for issue on 17 JUNE 2019, and are signed on their behalf by:


Peter Coleman
Director



COBRA BIOLOGICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017
(CONTINUED)

1. ACCOUNTING POLICIES

Basis of accounting

The financial statements are prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

The directors have concluded that it is appropriate to prepare the accounts on the going concern basis of accounting as they have received assurance from Zentricity Holding AB, the ultimate holding company, of its intention to provide financial support.

Financial instruments

Financial instruments are classified and accounted for according to the substance of the contractual arrangement as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of a company after deducting all of its liabilities.

2. PROFIT AND LOSS ACCOUNT

The company has not traded during the current or proceeding year and therefore no profit and loss account is presented.

3. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2018 £	2017 £
Trade and other payables		
Amounts due to group undertakings	438	438
	<u>438</u>	<u>438</u>

4. CALLED UP SHARE CAPITAL

	2018 £	2017 £
<i>Allotted, called up and fully paid</i>		
1 Ordinary shares of £1 each	1	1
	<u>1</u>	<u>1</u>

5. PROFIT AND LOSS ACCOUNT

	Profit and Loss Account £
Balance as at 1 January 2018	(439)
Balance as at 31 December 2018	<u>(439)</u>

6. CONTROL

At the balance sheet date the immediate parent undertaking was Cobra Biologics Holdings Limited, which was itself a wholly owned subsidiary of Cobra Biologics Holding AB, a company registered in Sweden.

Cobra Biologics Holding AB has produced consolidated financial statements, in accordance with International Financial Reporting Standards, which have been filed at Companies House, Crown Way, Cardiff.

At the balance sheet date the ultimate parent undertaking was Zentricity Holding AB, a company incorporated in Sweden, and the ultimate controlling party was Thomas Eldered.